Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Drug Firm AstraZeneca Sees 3rd Quarter Earnings Fall 12 Pct

By AP | November 10, 2016

Anglo-Swedish drugmaker AstraZeneca said Thursday that its third-quarter earnings fell 12 percent as its blockbuster cholesterol drug Crestor faced its first full quarter of competition in the United States from generic alternatives.

Operating profit declined to $1.03 billion from $1.17 billion in the same period a year earlier. Net income, which includes finance expenses and a one-time tax benefit of $319 million, rose 32 percent to $1.01 billion.

AstraZeneca has been cutting costs so it can devote more resources to cancer drugs. Sales of cancer treatments rose 19 percent to $867 million, driven by the introduction of the lung cancer drug Tagrisso and the ovarian cancer drug Lynparza.

U.S. sales of Crestor fell 82 percent to $124 million after generic competitors went on sale in July.

It remains unclear what impact the election of Donald Trump as U.S. president might have on pharmaceutical giants like AstraZeneca. The Republican leader has pledged to roll back Obamacare, the U.S. program to help individuals get health insurance.

During a call with analysts, CEO Pascal Soriot said he didn’t want to speculate on what the “new landscape” would look like, but that he hoped any new legislation would include policy that supports innovation.

“We also believe that we will have to continue to deal with price pressure,” he said.

(Source: Associated Press)

Related Articles Read More >

Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE